- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07934173
Study of Oncology-Adapted Pain Reprocessing Therapy for Aromatase Inhibitor Associated Musculoskeletal Symptoms in Breast Cancer Survivors (PRT-BC)
A Single-Arm Pilot Study of Oncology-Adapted Pain Reprocessing Therapy for Aromatase Inhibitor Associated Musculoskeletal Symptoms in Breast Cancer Survivors
The goal of this study is to evaluate the feasibility, acceptability, and preliminary clinical effects of an oncology-adapted Pain Reprocessing Therapy (PRT) intervention for women with aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). AIMSS is a common complication of aromatase inhibitor therapy for estrogen receptor-positive breast cancer and is associated with chronic pain, functional impairment, and premature discontinuation of endocrine therapy. The study will evaluate whether a six-session, manualized PRT intervention delivered remotely by trained palliative care therapists is feasible to implement and shows preliminary evidence of improving pain and physical function.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Jonathan Song
- Telefonnummer: 734-615-1279
- E-Mail: wmsong@umich.edu
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- History of ductal carcinoma in situ (DCIS) or Stage I-III estrogen receptor-positive breast cancer.
- Post-menopausal prior to starting AI or receiving luteinizing hormone-releasing hormone (LHRH) agonist therapy.
- Currently taking aromatase inhibitor therapy - anastrozole, exemestane, or letrozole - for adjuvant treatment of breast cancer or for chemoprevention.
- Current aromatase inhibitor therapy for at least 3 weeks and no more than 2 years prior to enrollment.
- Diagnosis of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS), defined as new or worsening joint pain and/or myalgias since starting aromatase inhibitor therapy,
- Have had at least 3 months of recovery since the last invasive surgery
- Adequate home internet access, defined as reliable access to a private internet connection or cellular data service that supports real time two-way audiovisual telehealth visits using the University of Michigan-approved video conferencing platform on a computer tablet or smartphone. Participants must be able to complete study telehealth visits from a private location.
Exclusion Criteria:
- Evidence of active cancer or progression of disease on most recent imaging, confirmed with the treating oncologist.
- Planned invasive surgery during Day 0-60, that could interfere with study participation, pain assessment, or functional outcomes.
- Concurrent inflammatory arthropathy or autoimmune disorder.
- Patient self-report or EMR documentation of moderate to severe memory impairment or a dementia diagnosis as these would interfere with the ability to understand and remember key elements of the intervention.
- Current participation in cognitive behavioral therapy or other psychological therapy for pain, as concurrent pain-focused psychotherapy could confound interpretation of the effects of the study intervention. If they received psychotherapy in the past, they must be at least 30 days from their last session to enroll.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Treatment Arm
PRT is a form of psychotherapy that incorporates pain neuroscience education (reframing chronic pain as a predominantly safe signal arising from the brain and nervous system rather than as something that only arises from damaged tissues) with mindfulness meditation and graded exposure strategies. . For this study, PRT has been adapted for the oncology and cancer survivorship context, and includes attention to cancer-related uncertainty, fear of recurrence, medical trauma, treatment-related bodily changes, and concerns about pain as a possible signal of cancer progression. The intervention is manualized and delivered over six sessions. |
All participants will be asked only to participate in six 30-45 min intervention sessions. Participants will need to complete the sessions in the order specified. PRT will be delivered remotely by trained palliative care therapists using a HIPAA compliant secure video conferencing platform. Each session will last approximately 30-45 minutes. The intervention will be delivered in English only. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Recruitment - Number
Zeitfenster: 11 months of recruitment activity
|
Number of approached patients who consent to participate. |
11 months of recruitment activity
|
|
Recruitment - proportion
Zeitfenster: 11 months of recruitment activity
|
Proportion of approached patients who consent to participate. |
11 months of recruitment activity
|
|
Retention - Assessments completed
Zeitfenster: 180 days
|
Mean number of post intervention assessments completed per subject; |
180 days
|
|
Retention - Proportion
Zeitfenster: 180 days
|
proportion of subjects completing the Day 60 and Day 180 assessments |
180 days
|
|
Intervention Uptake: PRT Sessions count
Zeitfenster: 60 days
|
Mean number of PRT sessions attended per subject |
60 days
|
|
Intervention Uptake: proportions of participants
Zeitfenster: 60 days
|
proportion completing at least 4 of 6 sessions and proportion completing all 6 sessions. |
60 days
|
|
Representativeness:
Zeitfenster: 11 months of enrollment activity
|
The demographic and clinical characteristics of enrolled participants vs. those of potentially eligible patients identified from the University of Michigan Rogel Cancer Center source population during the recruitment period. |
11 months of enrollment activity
|
|
Intervention fidelity.
Zeitfenster: 60 days of intervention
|
Intervention fidelity will be assessed through structured session checklists completed by interventionists after each visit, documenting delivery of required PRT components, session duration, and any deviations from the manual. |
60 days of intervention
|
|
Acceptability of PRT intervention
Zeitfenster: after 60 days of intervention
|
Treatment Acceptability and Adherence Scale (TAAS), a 10-item scale assessing perceived acceptability and usefulness of a behavioral intervention.(Milosevic et al., 2015) Scores above the midpoint - 35 out of 70 - will denote moderate acceptability of the intervention). |
after 60 days of intervention
|
|
Participant satisfaction
Zeitfenster: after 60 days of intervention
|
The CSQ-8 yields a total score ranging from 8 to 32, with higher scores indicating greater satisfaction. |
after 60 days of intervention
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Pain severity
Zeitfenster: up to 180 days
|
Pain severity will be measured using a 0-10 Numeric Rating Scale (NRS) assessing average pain over the prior 7 days, with anchors of 0 ("no pain") and 10 ("worst pain imaginable") (Jensen et al., 1986). |
up to 180 days
|
|
Change in Pain impact
Zeitfenster: up to 180 days
|
Pain impact will be assessed using the Pain, Enjoyment of Life, and General Activity (PEG) scale, a validated 3-item composite measure of pain severity and pain-related interference (Keller et al., 2004; Krebs et al., 2010). |
up to 180 days
|
|
Pain Interferece
Zeitfenster: up to 180 days
|
Pain interference will be assessed using the PROMIS Pain Interference Short Form 6b, a 6-item measure evaluating the extent to which pain interferes with daily activities, social participation, and enjoyment of life over the past 7 days |
up to 180 days
|
|
Physical Function T-scores
Zeitfenster: up to 180 days
|
Physical function will be measured using the PROMIS Physical Function 4a, a validated 4-item patient-reported measure of physical functioning. Scores will be converted to standardized T-scores, with higher scores indicating better physical function |
up to 180 days
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Hauptermittler: Maria Silveira, MD, University of Michigan
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- UMCC 2026.079
- U54AG0923230 (Andere Zuschuss-/Finanzierungsnummer: National Institutes of Health)
- HUM00292989 (Andere Kennung: University of Michigan Rogel Cancer Center)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Deidentified patient quantitative data and qualitative transcripts will be provided to a data repository at the University of Colorado which will gather the data on behalf of the National Institute of Aging.
IPD-Sharing-Zeitrahmen
within 12 months of last participant completing study
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .